 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Mind Medicine (MindMed) Inc. MNMD have skyrocketed 154% in the past three months against the industry's decline of 4.2%.The company is progressing well with the development of its lead...

MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade...

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 7,990,000 shares, a growth of 18.9% from the...

ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

This is a signal that ADMA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

ADMA Biologics (ADMA, $6.6) RSI Indicator left the overbought zone on March 28, 2024

This price move could be a signal that ADMA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

ADMA Biologics (ADMA, $6.75) price may drop as it broke higher Bollinger Band on Mar 27, 2024

Shares of Moderna MRNA rose 3% on Wednesday after management announced positive clinical updates at its Vaccines Day Event, highlighting its pipeline progress.While the company provided an update on...

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Syndax Pharmaceuticals SNDX stock rose 7.6% on Mar 27 after it announced a day before that the FDA had granted a priority review to its new drug application (NDA) for pipeline candidate revumenib...

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

This is a signal that ADMA's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

ADMA Biologics (ADMA, $6.5) Stochastic Oscillator left the overbought zone on March 26, 2024

ADMA Biologics (ADMA, $6.5) RSI Indicator left the overbought zone on March 26, 2024

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Volume (M)	2.98M
52-Wk High	$6.76
52-Wk Low	$3.06

ADMA Adma Biologics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals